Nexthera Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Nexthera Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-167,866	Closed	-$1.73M	–	50
2016 Q4	$1.73M	Hold	167,866	–	–	1.01%	25
2016 Q3	$1.7M	Sell	167,866 -15,134	-8%	-$165K	1.04%	26
2016 Q2	$2.06M	Hold	183,000	–	–	1.78%	13
2016 Q1	$2.5M	Hold	183,000	–	–	2.59%	11
2015 Q4	$3.47M	Buy	+183,000	New	+$3.98M	4.93%	7

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital's CNCE Position: Q1 2017 in Review

Nexthera Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 167,866 shares — an estimated $1.73M sold.

Nexthera Capital first reported a position in CNCE in Q4 2015 and held it in 5 quarters. The position peaked at $3.47M in Q4 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Nexthera Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Nexthera Capital sold 167,866 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.73M.
Nexthera Capital first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 5 quarters.
Nexthera Capital's Concert Pharmaceuticals, Inc. position peaked at $3.47M in Q4 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.